Compare Hycroft Mining Holding Corporation Class A Common Stock (HYMC) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hycroft Mining Holding Corporation Class A Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Hycroft Mining Holding Corporation Class A Common Stock trades at $16.45 (market cap $1.64B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 6.4× Hycroft Mining Holding Corporation Class A Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Hycroft Mining Holding Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hycroft Mining Holding Corporation Class A Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| HYMC | PCVX | |
|---|---|---|
Market Cap | $1.64B | $10.51B |
Volume | 1,750,098 | 2,644,694 |
Sector | Basic Materials | Health |
52-Week High | $55.74 | $73.82 |
52-Week Low | $6.75 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $1.42B | $9.14B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hycroft Mining Holding Corporation Class A Common Stock
Hycroft Mining Holding Corporation is a US mining company that owns and operates the Hycroft Mine, a gold and silver deposit in northern Nevada, producing and selling gold and silver from open-pit mining operations.
Read more on HYMC →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
